Rezzayo is indicated to be given as a weekly intravenous drip for a minimum of 14 days until Candida is no longer present in the bloodstream. Credit: TommyStockProject / Shutterstock.com.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Napp Pharmaceuticals’ new antifungal treatment for invasive candidiasis, Rezzayo (rezafungin).

The fungal infection is caused by the yeast candida, which can affect areas of the body such as the blood and vital organs.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Rezzayo is given as a weekly intravenous drip for at least 14 days until candida is no longer present in the bloodstream.

Rezafungin is the active ingredient of the treatment and works by inhibiting an enzyme essential for fungal cell wall synthesis, rendering the fungal cells fragile and halting their growth.

The approval of Rezzayo is based on the results of a Phase III randomised, double-blind and controlled clinical trial.

This study involved 187 invasive candidiasis patients who were randomly given rezafungin or another antifungal medication, caspofungin, for two to four weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

At the 14-day mark, 55 subjects treated with rezafungin were cured, versus 57 in the caspofungin arm.

By the 30th day, 22 subjects on rezafungin had died from various causes, in contrast to 20 on caspofungin.

Hypokalaemia, diarrhoea and fever were the most common side effects of Rezzayo.

MHRA healthcare quality and access interim executive director Julian Beach said: “Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.

“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review.”